[Terazosine in the treatment of benign prostatic hypertrophy]

A review is presented of the current status of terazosin in the treatment of BPH. The results of many clinical trials indicate a definite and significant improvement in both subjective and objective parameters. Attention is drawn to certain possible problems and limitations of placebo controlled trials with alpha-adrenergic blockers for BPH. Parameter improvements appear to be dose-related, and the importance of dose titration is stressed. The pharmacokinetic properties of the drug enables a once daily administration. Long term treatment for more than two years indicates that efficacy is maintained.